Eli Lilly and Company

Advisor Statistics - HTA

United Kingdom

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Healthcare, BiotechnologyIndustries

Requirements

Candidates should possess a PhD in Statistics or a related field, with a minimum of 3 years of experience or an MSc degree with a minimum of 6 years of experience. Expertise in Health Technology Assessment (HTA), health outcomes research, and/or real-world evidence is required. Strong knowledge of statistical theory and methodology, including experimental design and causal inference, is essential.

Responsibilities

The Advisor Statistics - HTA will provide technical statistical leadership to data-related research in Health Technology Assessment (HTA) and reimbursement, collaborating with multiple partners across various functions and geographies. They will translate strategic needs into innovative statistical solutions, utilizing efficient or innovative approaches in economic modeling and clinical trials. The role involves keeping up-to-date with statistical methodology, ensuring high-quality statistical support for projects, overseeing external suppliers, and influencing cross-functional team members regarding research methods. Furthermore, the position requires communicating study results via payer submissions, publications, or presentations, supporting responses to payer queries, and contributing to internal and external scientific interactions with decision-making agencies and healthcare professionals.

Skills

Statistical analysis
Health Technology Assessment (HTA)
Meta-analysis
Economic modeling
Clinical trials
Data analysis
Reimbursement strategies

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Key Metrics

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI